G. Kieczykowski

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

G. Scapin, Suresh B. Singh, N. Thornberry, 2007, Bioorganic & medicinal chemistry letters.

1,3,8-Triazaspiro[4.5]decane-2,4-diones as efficacious pan-inhibitors of hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) for the treatment of anemia.

J. Demartino, E. Sherer, P. Váchal, 2012, Journal of medicinal chemistry.

Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.

P. Davies, M. Maccoss, C. Raab, 2009, Journal of medicinal chemistry.

Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity.

K. Lyons, Y. Yang, M. Goulet, 2001, Bioorganic & medicinal chemistry letters.

Preparation of (4-Amino-1-Hydroxybutylidene)bisphosphonic Acid Sodium Salt, MK-217 (Alendronate Sodium). An Improved Procedure for the Preparation of 1-Hydroxy-1,1-bisphosphonic Acids

D. Melillo, I. Shinkai, G. Kieczykowski, 1995 .

Catalytic, Enantioselective Synthesis of Taranabant, a Novel, Acyclic Cannabinoid-1 Receptor Inverse Agonist for the Treatment of Obesity

Alex M. Chen, Jeff Strine, Cheng-yi Chen, 2007 .

Synthesis and characterization of a potent, selective, radiolabeled substance-P antagonist for NK1 receptor quantitation: ([18F]SPA-RQ).

Tove Grönroos, Merja Haaparanta, Jarmo Hietala, 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

Discovery of substituted 8,9-dicarboxyldibenzo [2,3:5,6] bicyclo [5.2.0] nonan-4-ones with moderate binding affinity to the endothelin ETA and ETB receptors

David L. Williams, W. Greenlee, R. Rivero, 1995 .